NASDAQ:CRME - Cardiome Pharma Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$2.33 -0.05 (-2.10 %)
(As of 08/17/2018 04:00 PM ET)
Previous Close$2.33
Today's Range$2.30 - $2.45
52-Week Range$1.29 - $4.84
Volume90,444 shs
Average Volume135,322 shs
Market Capitalization$81.25 million
P/E Ratio-2.59
Dividend YieldN/A
Cardiome Pharma logoCardiome Pharma Corp., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of patients suffering from heart diseases. It offers BRINAVESS (vernakalant (IV)) for the conversion of recent onset atrial fibrillation to sinus rhythm in adults; and AGGRASTAT, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients. The company also provides ESMOCARD and ESMOCARD LYO short-acting beta-blockers used to control rapid heart rate; XYDALBA, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections; and TREVYENT for the treatment of pulmonary arterial hypertension. It has operations in Canada, the United States, Europe, and internationally. The company was formerly known as Nortran Pharmaceuticals Inc. and changed its name to Cardiome Pharma Corp. in June 2001. Cardiome Pharma Corp. was founded in 1986 and is headquartered in Vancouver, Canada.

Receive CRME News and Ratings via Email

Sign-up to receive the latest news and ratings for CRME and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity Ratio4.31
Current Ratio3.97
Quick Ratio3.99


Trailing P/E Ratio-2.59
Forward P/E Ratio-3.03
P/E GrowthN/A

Sales & Book Value

Annual Sales$24 million
Price / Sales3.39
Cash FlowN/A
Price / CashN/A
Book Value$0.26 per share
Price / Book8.96


EPS (Most Recent Fiscal Year)($0.90)
Net Income$-29,810,000.00
Net Margins-125.98%
Return on Equity-164.75%
Return on Assets-47.61%


Outstanding Shares34,870,000
Market Cap$81.25 million

Cardiome Pharma (NASDAQ:CRME) Frequently Asked Questions

What is Cardiome Pharma's stock symbol?

Cardiome Pharma trades on the NASDAQ under the ticker symbol "CRME."

How were Cardiome Pharma's earnings last quarter?

Cardiome Pharma Co. (NASDAQ:CRME) announced its quarterly earnings data on Tuesday, May, 15th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by $0.02. The biopharmaceutical company earned $6.54 million during the quarter, compared to analyst estimates of $7.34 million. Cardiome Pharma had a negative net margin of 125.98% and a negative return on equity of 164.75%. View Cardiome Pharma's Earnings History.

What price target have analysts set for CRME?

3 brokers have issued 12 month target prices for Cardiome Pharma's stock. Their forecasts range from $5.00 to $10.00. On average, they anticipate Cardiome Pharma's share price to reach $7.50 in the next twelve months. This suggests a possible upside of 221.9% from the stock's current price. View Analyst Price Targets for Cardiome Pharma.

What is the consensus analysts' recommendation for Cardiome Pharma?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cardiome Pharma in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cardiome Pharma.

What are Wall Street analysts saying about Cardiome Pharma stock?

Here are some recent quotes from research analysts about Cardiome Pharma stock:
  • 1. According to Zacks Investment Research, "Cardiome Pharma Corp. is a product-focused cardiovascular drug development company with two clinical drug programs focused on atrial arrhythmia (intravenous and oral dosing), and a pre-clinical program directed at improving cardiovascular function. " (11/14/2017)
  • 2. Canaccord Genuity analysts commented, "Date and time of first dissemination: August 21, 2017, 09:42 ET Date and time of production: August 21, 2017, 09:42 ET Target Price / Valuation Methodology: Cardiome Pharma Corp. – CRME Discounted cash flow analysis supports an $8 valuation for CRME shares Our discounted cash flow (DCF) analysis leads us to a 12-month valuation of around $8/share for CRME, assuming continued progress on the Brinavess Canada and Xydalba launches along with a potential Trevyent launch in 2019. We estimate a weighted average cost of capital (WACC) of 11.2%, which assumes an 88% equity/total capital structure at a 10.3% cost of equity capital and a 12% debt/total capital structure at a 14% cost of debt. We use a long-term estimated tax rate of 22% and a terminal growth decline of 1% in our analysis. For cash management purposes, our analysis assumes an equity raise in 2H/17 but management has not publicly commented on the possibility of future capital raises. Risks to achieving Target Price / Valuation: Cardiome Pharma Corp. – CRME OUS payers and providers can be more difficult to predict – Given the relative lack of market data compared to the US coupled with a fragmented payer landscape, variability in physician training and standard of care modalities, and different preferences in patient populations in OUS markets, the marketability of a product in these environments can be more difficult to predict than in the US." (8/21/2017)

Who are some of Cardiome Pharma's key competitors?

Who are Cardiome Pharma's key executives?

Cardiome Pharma's management team includes the folowing people:
  • Dr. William L. Hunter, Pres, CEO & Director (Age 55)
  • Ms. Sheila M. Grant MBA, Chief Operating Officer
  • Mr. David D. McMasters, Gen. Counsel (Age 59)
  • Mr. Hugues Sachot, Chief Commercial Officer
  • Mr. Justin A. Renz, Chief Financial Officer (Age 46)

Has Cardiome Pharma been receiving favorable news coverage?

News articles about CRME stock have been trending positive on Saturday, according to Accern. The research firm ranks the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cardiome Pharma earned a daily sentiment score of 0.28 on Accern's scale. They also gave news coverage about the biopharmaceutical company an impact score of 47.35 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term. View Recent Headlines for Cardiome Pharma.

How do I buy shares of Cardiome Pharma?

Shares of CRME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cardiome Pharma's stock price today?

One share of CRME stock can currently be purchased for approximately $2.33.

How big of a company is Cardiome Pharma?

Cardiome Pharma has a market capitalization of $81.25 million and generates $24 million in revenue each year. The biopharmaceutical company earns $-29,810,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis. Cardiome Pharma employs 120 workers across the globe.

How can I contact Cardiome Pharma?

Cardiome Pharma's mailing address is 1441 Creekside Drive 6th Floor, Vancouver A1, V6J 4S7. The biopharmaceutical company can be reached via phone at 604-677-6905 or via email at [email protected]

MarketBeat Community Rating for Cardiome Pharma (NASDAQ CRME)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  213 (Vote Outperform)
Underperform Votes:  202 (Vote Underperform)
Total Votes:  415
MarketBeat's community ratings are surveys of what our community members think about Cardiome Pharma and other stocks. Vote "Outperform" if you believe CRME will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRME will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/18/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.